Literature DB >> 10671647

Pharmacogenetics in the practice of laboratory medicine.

M W Linder1, R Valdes.   

Abstract

BACKGROUND: The clinical laboratory forms an essential bridge between fundamental discoveries in biological sciences and their transition into effective medical practice. The genetic basis for individuality in drug metabolism and response is the result of a finite number of inherited sequence variants (alleles) of genes encoding drug-metabolizing enzymes and drug receptors. Pharmacogenetics (PG) links differences in gene structure with pharmacological differences in pharmacokinetics and pharmacodynamics. The next step in the process of applying PG (or pharmacogenomic) information to individualized therapeutic management is dissemination of this information to practicing physicians by clinical laboratorians. Transitioning PG analysis into clinical practice will require professionals in laboratory medicine to identify relevant polymorphisms, develop sensitive and specific testing strategies, and, in conjunction with physicians and pharmacologists, communicate interpretive guidelines regarding appropriate indications for testing and rational dose adjustment. We review these concepts and provide examples of how PG can be applied to support therapeutic decision making.

Mesh:

Substances:

Year:  1999        PMID: 10671647     DOI: 10.1016/s1084-8592(99)80013-7

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  5 in total

1.  Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.

Authors:  Cierra N Sharp; Mark W Linder; Roland Valdes
Journal:  Crit Rev Clin Lab Sci       Date:  2019-11-02       Impact factor: 6.250

2.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  GenDrux: a biomedical literature search system to identify gene expression-based drug sensitivity in breast cancer.

Authors:  Chiquito Crasto; Dajie Luo; Feliciano Yu; Andres Forero; Dongquan Chen
Journal:  BMC Med Inform Decis Mak       Date:  2011-05-05       Impact factor: 2.796

4.  Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance.

Authors:  Alan Hb Wu
Journal:  Clin Proteomics       Date:  2011-07-28       Impact factor: 3.988

5.  Pharmacogenetic And Tumour Drugs.

Authors:  Elizabeta Topic
Journal:  EJIFCC       Date:  2005-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.